---
audienceLevel: patient
cancerTypes:
- breast
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ribociclib Succinate and Letrozole - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ribociclib-succinate-and-letrozole
version: v1
---

# Ribociclib Succinate and Letrozole - NCI

# Ribociclib Succinate and Letrozole

Placeholder slot

(RY-boh-SY-klib SUK-sih-nayt â€¦ LEH-truh-zole)

Kisqali Femara Co-Pack combines two drugs into one package: ribociclib succinate (Kisqali) and letrozole (Femara). Ribociclib succinate is a targeted therapy drug that blocks proteins called CDK4 and CDK6 that cancer cells need to grow. Letrozole is a hormone therapy and targeted therapy drug that blocks a protein called aromatase, which the body uses to make estrogen. Blocking aromatase lowers estrogen levels, which helps slow or stop the growth of breast cancer cells that need estrogen to grow.

US Brand Name(s)

Kisqali Femara Co-Pack

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f&audience=consumer)

## Use in Cancer

The [ribociclib succinate](/Common/PopUps/popDefinition.aspx?id=787678&version=Patient&language=English) and [letrozole](/Common/PopUps/popDefinition.aspx?id=45421&version=Patient&language=English) co-pack
is approved to treat:

- **[breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=Patient&language=English)** that is [hormone receptor positive](/Common/PopUps/popDefinition.aspx?id=788029&version=Patient&language=English) (HR+) and [HER2 negative](/Common/PopUps/popDefinition.aspx?id=774531&version=Patient&language=English) (HER2-). It is used:
- for stage II or stage III [early breast cancer](/Common/PopUps/popDefinition.aspx?id=446564&version=Patient&language=English) that is at high risk of coming back
- as the first [hormone-based therapy](/Common/PopUps/popDefinition.aspx?id=45110&version=Patient&language=English) for cancer that has spread

Ribociclib succinate and letrozole
are also available separately as ribociclib succinate and letrozole. For more information that may apply to these drugs, see the Drug Information Summaries for [Ribociclib Succinate](/about-cancer/treatment/drugs/ribociclib) and [Letrozole](/about-cancer/treatment/drugs/letrozole).

## More About Ribociclib Succinate and Letrozole

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/816801) - Detailed scientific definition and other names for this drug.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer](https://www.cancer.gov/news-events/cancer-currents-blog/2021/ribociclib-improves-metastatic-breast-cancer-survival)

[Hormone Therapy to Treat Breast Cancer](https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ribociclib Succinate/letrozole](https://www.cancer.gov/research/participate/clinical-trials/intervention/C154675) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
